FGFR1 and acute myeloid leukemia: Identification of AML that could potentially benefit from anti-FGFR1 treatment based on expression levels alone, however, may be an underestimate, since there may be mutational activation or other mechanisms of enhanced protein activation that are independent of the expression level.